Drug · CHEMBL1502
PANTOPRAZOLE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PANTOPRAZOLE. Drugs and targets, record CHEMBL1502. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1502
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Altopan, BY 1023, BY-1023, BY1023, NSC-759257, Pantocid, Pantoloc, Pantoprazol, Pantozol, SK&F 96022, SK&F-96022, SK-96022, SKF-96022, Zovanta
- ChEMBL
- Open Targets' highest stage
- Approval, for 2 of its 23 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ATP4A | Potassium-transporting ATPase | Potassium-transporting ATPase inhibitor | INHIBITOR | https://conductscience.org/library/genes/495 |
| ATP4B | Potassium-transporting ATPase | Potassium-transporting ATPase inhibitor | INHIBITOR | https://conductscience.org/library/genes/496 |
Source ChEMBL
Diseases23
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| gastroesophageal reflux disease | Approval | ATC, EMA Human Drugs and TTD | 38 | 31 | https://conductscience.org/library/drugs?q=MONDO_0007186 |
| Helicobacter pylori infectious disease | Phase 3 | ClinicalTrials.gov | 12 | 12 | https://conductscience.org/library/drugs?q=MONDO_0006781 |
| peptic ulcer disease | Approval | ATC | 5 | 4 | https://conductscience.org/library/drugs?q=MONDO_0004247 |
| type 2 diabetes mellitus | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005148 |
| acute kidney injury | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0002492 |
| esophagitis | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0001409 |
| osteoarthritis, knee | Unknown | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005416 |
| Barrett esophagus | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0013662 |
| Gastrointestinal hemorrhage | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0002239 |
| Laryngopharyngeal Reflux | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_1001355 |
1 to 10 of 23Source Open Targets
See all 23 diseasesTrials169
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02467621 | Stress Ulcer Prophylaxis in the Intensive Care Unit | Phase 4 | 3,350 | 2019-06-07 | pantoprazole | Its name | ClinicalTrials.gov |
| NCT01493557 | A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation | Phase 4 | 1,067 | 2015-10-05 | pantoprazole | Its name | ClinicalTrials.gov |
| NCT02359435 | Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection | 440 | 2016-02-10 | pantoprazole | Its name | ClinicalTrials.gov | |
| NCT02159976 | Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea | 390 | 2019-05-13 | pantoprazole | Its name | ClinicalTrials.gov | |
| NCT02547038 | Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy | 352 | 2019-06-10 | pantoprazole | Its name | ClinicalTrials.gov | |
| NCT02541864 | Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication | 330 | 2017-08-10 | pantoprazole | Its name | ClinicalTrials.gov | |
| NCT01769365 | Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection | Phase 4 | 307 | 2015-10-06 | pantoprazole | Its name | ClinicalTrials.gov |
| NCT00365300 | Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD) | Phase 3 | 129 | 2010-01-07 | pantoprazole | Its name | ClinicalTrials.gov |
| NCT01477320 | Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients. | 124 | 2018-01-16 | pantoprazole | Its name | ClinicalTrials.gov | |
| NCT00825630 | 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors) | Phase 4 | 123 | 2011-10-07 | pantoprazole | Its name | ClinicalTrials.gov |
1 to 10 of 169
See all 169 trialsComparisons in its trials53
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Proton Pump Inhibitor (PPI) vs Normal Saline: Number of Participants With Clinically Important GI Bleeding, Pneumonia, Clostridium Difficile Infection or Acute Myocardial Ischemia | 360 of 1,644 | 372 of 1,647 | 3,291 | NCT02467621 | Trial comparisons |
| Proton Pump Inhibitor (PPI) vs Normal Saline: Number of Participants With One or More Infectious Adverse Events | 276 of 1,644 | 279 of 1,647 | 3,291 | NCT02467621 | Trial comparisons |
| Proton Pump Inhibitor (PPI) vs Normal Saline: Number of Serious Adverse Reactions | 0 of 1,644 | 0 of 1,647 | 3,291 | NCT02467621 | Trial comparisons |
| Proton Pump Inhibitor (PPI) vs Normal Saline: Number of Participants With Clinically Important GI Bleeding | 41 of 1,644 | 69 of 1,647 | 3,291 | NCT02467621 | Trial comparisons |
| Proton Pump Inhibitor (PPI) vs Normal Saline: serious adverse events | 0 of 1,644 | 0 of 1,647 | 3,291 | NCT02467621 | Trial comparisons |
| Proton Pump Inhibitor (PPI) vs Normal Saline: Mortality | 510 of 1,642 | 499 of 1,640 | 3,282 | NCT02467621 | Trial comparisons |
| Proton Pump Inhibitor (PPI) vs Normal Saline: deaths from any cause | 610 of 1,635 | 601 of 1,626 | 3,261 | NCT02467621 | Trial comparisons |
| Proton Pump Inhibitor (PPI) vs Normal Saline: Mortality | 610 of 1,635 | 601 of 1,626 | 3,261 | NCT02467621 | Trial comparisons |
| Reverse Hybrid Therapy vs Standard Triple Therapy: Number of Participants in Which H. Pylori Was Eradicated | 206 of 220 | 191 of 220 | 440 | NCT02359435 | Trial comparisons |
| Reverse Hybrid Therapy vs Standard Triple Therapy: serious adverse events | 0 of 220 | 0 of 220 | 440 | NCT02359435 | Trial comparisons |
1 to 10 of 53
See all 53 comparisons in its trialsPapers from its trials98
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1502
GET https://conductscience.org/api/drugs/v1/CHEMBL1502/diseases?page=2